Short Communication

Cancer Immunology, Immunotherapy

, Volume 61, Issue 7, pp 1149-1153

First online:

Uterine leiomyosarcoma diffusely express disialoganglioside GD2 and bind the therapeutic immunocytokine 14.18-IL2: implications for immunotherapy

  • Angela J. ZiebarthAffiliated withDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Alabama at Birmingham Email author 
  • , Mildred A. FelderAffiliated withDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Wisconsin Madison
  • , Josephine HarterAffiliated withDepartment of Pathology, University of Wisconsin Madison
  • , Joseph P. ConnorAffiliated withDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Alabama at BirminghamDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Wisconsin Madison

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Uterine leiomyosarcoma comprises <1 % of uterine malignancies and is known for its clinically aggressive course. Extrapelvic recurrences are common and often lethal. No adjuvant therapies have been shown to significantly improve overall survival, highlighting the need for new and novel therapies. Our objective was to determine whether GD2-specific immunocytokine therapy may be explored for the treatment for uterine leiomyosarcoma. To do so, frozen tissue sections were obtained from the Gynecologic Oncology Group tumor bank and evaluated by immunohistochemistry (IHC) for GD2 expression using both the parent mouse monoclonal antibody 14G2A and immunocytokine 14.18-IL2 generated from the 14G2A sequence. Immunoreactivity was detected by avidin–biotin complex with DAB substrate. Specimens were reviewed by a pathologist with light microscopy and classified as negative, 1+, 2+ or 3+, compared to human melanoma cells as positive control and tissue incubated in the absence of primary antibody as negative control. GD2 was diffusely present in all evaluable samples. 10 tumors (67 %) demonstrated 3+ IHC intensity for GD2, two tumors (13 %) demonstrated 2+ intensity, and 3 (20 %) tumors demonstrated 1+ intensity. Eleven cases had sufficient tissue to assess 14.18-IL2 binding. All 11 cases bound 14.18-IL2 in a pattern identical to the parent antibody. Uterine leiomyosarcoma diffusely express GD2 and bind the therapeutic immunocytokine 14.18-IL2. This warrants further exploration to determine whether immunocytokine therapy may have a clinical role in the management of these aggressive tumors.

Keywords

14.18 Uterine leiomyosarcoma Immunotherapy GD2 Sarcoma